Scholarlink

<p>Novel immunotherapies such as chimeric antigen receptor T‑cell therapy (CAR T‑cell therapy) and bispecific T‑cell engagers (BiTEs) have transformed the treatment of hematologic malignancies in recent years. Despite their high efficacy, they pose considerable risks, particularly for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Both typically occur within the first 2&#xa0;weeks after therapy and may require admission to an intensive care unit (ICU). Other relevant side effects include persistent cytopenias, hypogammaglobulinemia, and increased susceptibility to infections. These long-term complications are gaining importance and require structured follow-up strategies. Up to 35% of patients undergoing CAR T‑cell therapy require intensive care, mostly due to CRS or ICANS. Nevertheless, the rates of organ support and ICU mortality remain comparatively low, indicating that these toxicities are, in principle, manageable. The severe toxicities of these novel therapies increasingly pose ethical challenges in intensive care. Decision-making frameworks such as the “ICU trial” model can provide valuable guidance. This article offers a&#xa0;comprehensive overview of acute and delayed side effects of immune-based therapies, their intensive care management, and current strategies for optimizing patient care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Moderne Immuntherapie und Notfallsituationen

  • 期刊论文

  • 发表日期：

    2025年9月2日

查看全文
  • Judit Grans-Siebel,
  • Jorge Garcia Borrega,
  • Boris Böll,
  • Franziska Bach

摘要

Novel immunotherapies such as chimeric antigen receptor T‑cell therapy (CAR T‑cell therapy) and bispecific T‑cell engagers (BiTEs) have transformed the treatment of hematologic malignancies in recent years. Despite their high efficacy, they pose considerable risks, particularly for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Both typically occur within the first 2 weeks after therapy and may require admission to an intensive care unit (ICU). Other relevant side effects include persistent cytopenias, hypogammaglobulinemia, and increased susceptibility to infections. These long-term complications are gaining importance and require structured follow-up strategies. Up to 35% of patients undergoing CAR T‑cell therapy require intensive care, mostly due to CRS or ICANS. Nevertheless, the rates of organ support and ICU mortality remain comparatively low, indicating that these toxicities are, in principle, manageable. The severe toxicities of these novel therapies increasingly pose ethical challenges in intensive care. Decision-making frameworks such as the “ICU trial” model can provide valuable guidance. This article offers a comprehensive overview of acute and delayed side effects of immune-based therapies, their intensive care management, and current strategies for optimizing patient care.